The relationship between granulation pattern and pharmacological treatment response has been well established in somatotropinomas, where DG tumors generally exhibit a higher SSTR2 expression and respond favorably to first-generation somatostatin analogs, whereas SG tumors tend to present a lower SSTR2 and relatively higher SSTR5 expression, making them more responsive to Pasireotide [56,57,58]. Here, SSTR2 is linked to growth hormone-producing pituitary gland neoplasm.